Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 26, 2023; 11(12): 2621-2630
Published online Apr 26, 2023. doi: 10.12998/wjcc.v11.i12.2621
Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease
Matthew D McCormack, Natasha A Wahedna, David Aldulaimi, Peter Hawker
Matthew D McCormack, Natasha A Wahedna, David Aldulaimi, Peter Hawker, Department of Gastroenterology, South Warwickshire NHS Foundation Trust, Warwick Hospital, Warwick CV34 5BW, United Kingdom
Author contributions: McCormack MD and Wahedna NA carried out literature search, data summary, review and draft manuscript preparation; McCormack MD and Wahedna NA wrote the manuscript in consultation with Aldulaimi D and Hawker who supervised; all authors read and approved the final manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Matthew D McCormack, MBChB, Doctor, Department of Gastroenterology, South Warwickshire NHS Foundation Trust, Warwick Hospital, Lakin Road, Warwick CV34 5BW, United Kingdom. m.mccormack3@nhs.net
Received: September 19, 2022
Peer-review started: September 19, 2022
First decision: October 19, 2022
Revised: February 7, 2023
Accepted: March 24, 2023
Article in press: March 24, 2023
Published online: April 26, 2023
Processing time: 218 Days and 3.6 Hours
Core Tip

Core Tip: For patients with difficult to treat or refractory inflammatory bowel disease (IBD), biologic therapy and combination therapy with small molecule agents has helped improve patient outcomes and maintenance success. There is growing interest in the use of dual biologic therapy in IBD but published data remains limited. Whilst initial data suggests positive effects on reduction in morbidity, more studies are still required in this emerging area with further comparison of different biologic combinations and their safety profiles.